|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...8687888990919293949596...156157» |
- New P1 trial: Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA) (clinicaltrials.gov) - Aug 21, 2014
P1, N=9, Not yet recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
- | teriflunomide / Generic mfg.
Trial completion: A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - Aug 21, 2014
P1, N=12, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed
- ||| Trial completion, Monotherapy: A Retrospective, Observational Chart Review of Biologics in Monotherapy Versus the Combination Biologic Plus Methotrexate in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=476, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed
- Diastat (diazepam rectal gel) / Bausch Health
Trial completion, Enrollment change: MDDC: Model Driven Diabetes Care (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=30, Completed, Sponsor: University Hospital of North Norway
Recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 30
- Trial completion: Effect of High-protein High-fiber Diet in Patients With Autoimmune Hepatitis (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=40, Completed, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Active, not recruiting --> Completed | N=40 --> 30 Recruiting --> Completed
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Trial primary completion date: An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=51, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> May 2014
- || Trial primary completion date: Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns (clinicaltrials.gov) - Aug 19, 2014
P4, N=240, Recruiting, Sponsor: Allergan
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> May 2014 Trial primary completion date: Dec 2014 --> Jun 2015
- |||| Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: ASCEND: A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 19, 2014
P3, N=890, Active, not recruiting, Sponsor: Biogen Idec
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: Dec 2014 --> Oct 2015
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=1070, Recruiting, Sponsor: UCB, Inc.
Trial primary completion date: Dec 2014 --> Oct 2015 N=500 --> 1070
- ||| BIIB023 / Biogen
Enrollment change: ATLAS: BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (clinicaltrials.gov) - Aug 19, 2014
P2, N=211, Recruiting, Sponsor: Biogen Idec
N=500 --> 1070 N=300 --> 211
- Biomarker: Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=170, Not yet recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
- | New P4 trial: Progressive Resistance Exercise in Rheumatoid Arthritis (clinicaltrials.gov) - Aug 19, 2014
P4, N=60, Recruiting, Sponsor: Federal University of São Paulo
- |||||||||| dalfampridine / Generic mfg.
New P3 trial: ENHANCE: Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (clinicaltrials.gov) - Aug 19, 2014
P3, N=590, Not yet recruiting, Sponsor: Biogen Idec
- Enrollment closed: Wahls Paleo Diet and Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=45, Active, not recruiting, Sponsor: University of Iowa
N=300 --> 211 Recruiting --> Active, not recruiting
- Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: PK and PD Study of Natalizumab in Pediatric Subjects With RRMS (clinicaltrials.gov) - Aug 19, 2014
P1, N=12, Recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2015 --> Apr 2015
- l-methylfolate / Generic mfg.
Trial primary completion date: Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) (clinicaltrials.gov) - Aug 19, 2014
P1, N=40, Active, not recruiting, Sponsor: University of Iowa
Trial primary completion date: Sep 2015 --> Apr 2015 Trial primary completion date: Jan 2014 --> Jan 2016
- Trial termination, Trial primary completion date: Ascension (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=59, Terminated, Sponsor: Ascension Orthopedics, Inc.
Trial primary completion date: Jan 2014 --> Jan 2016 Recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Jul 2014; Study was terminated due to PI leaving the institution
- dimethyl fumarate / Generic mfg.
Preclinical: Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=20, Recruiting, Sponsor: Yale University
- NN1953 / Novo Nordisk
New P1 trial: A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 19, 2014
P1, N=66, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| mezagitamab (TAK-079) / Takeda
New P1 trial: A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants (clinicaltrials.gov) - Aug 19, 2014
P1, N=82, Recruiting, Sponsor: Takeda
- ||| ZB-168 / Zura Bio
Enrollment open: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Aug 19, 2014
P1, N=60, Recruiting, Sponsor: Pfizer
Recruiting --> Terminated | Trial primary completion date: Oct 2022 --> Jul 2014; Study was terminated due to PI leaving the institution Not yet recruiting --> Recruiting
- Biomarker, Enrollment closed: An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Aug 19, 2014
P1, N=67, Completed, Sponsor: Novo Nordisk A/S
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- DiabeCell (immunoprotected [alginate-encapsulated] porcine islets) / Living Cell Technologies
Trial completion: Open-label Investigation of the Safety and Effectiveness of DIABECELL (clinicaltrials.gov) - Aug 19, 2014
P1/2, N=8, Completed, Sponsor: Living Cell Technologies
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Aspart-PH20 (insulin aspart/rHuPH20) / Halozyme, Lispro-PH20 (insulin lispro/rHuPH20) / Halozyme
Trial completion, Enrollment change, Trial primary completion date: Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 19, 2014
P2, N=135, Completed, Sponsor: Halozyme Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=110 --> 135 | Trial primary completion date: Sep 2013 --> Aug 2011
- Clinical: Massage Therapy in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Aug 18, 2014
P=N/A, N=30, Not yet recruiting, Sponsor: McGill University Health Center
- ||| staphylococcal protein A (PRTX-100) / Protalex
Trial completion, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 18, 2014
P1, N=61, Completed, Sponsor: Protalex, Inc.
Active, not recruiting --> Completed | N=110 --> 135 | Trial primary completion date: Sep 2013 --> Aug 2011 Active, not recruiting --> Completed
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment change, Trial withdrawal, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Aug 15, 2014
P2, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed N=42 --> 0 | Not yet recruiting --> Withdrawn
- Orencia (abatacept) / BMS
Enrollment change: ACCLAIM: A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (clinicaltrials.gov) - Aug 15, 2014
P2, N=65, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=42 --> 0 | Not yet recruiting --> Withdrawn N=123 --> 65
- Enrollment change, Trial primary completion date: A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement (clinicaltrials.gov) - Aug 15, 2014
P4, N=100, Terminated, Sponsor: DePuy International
N=123 --> 65 N=200 --> 100 | Trial primary completion date: Jan 2013 --> Sep 2009
- Clinical: Tear Proteins, Conjunctival Cells and Imaging Eyes in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=80, Recruiting, Sponsor: Singapore National Eye Centre
- ||||| dimethyl fumarate / Generic mfg.
New P4 trial: IIT9: Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation (clinicaltrials.gov) - Aug 15, 2014
P4, N=100, Recruiting, Sponsor: Rocky Mountain MS Research Group, LLC
- | New P2 trial, PK/PD data: Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 15, 2014
P2, N=170, Terminated, Sponsor: Boehringer Ingelheim
- | Rebif (human IFN-β-1a) / EMD Serono
Trial completion, Trial primary completion date: ReNew: Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=49, Completed, Sponsor: Merck KGaA
N=200 --> 100 | Trial primary completion date: Jan 2013 --> Sep 2009 Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> Apr 2013
- Baqsimi (glucagon intranasal dry powder) / Amphastar
Trial primary completion date: Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes (clinicaltrials.gov) - Aug 15, 2014
P2/3, N=48, Recruiting, Sponsor: T1D Exchange Clinic Network Coordinating Center
Active, not recruiting --> Completed | Trial primary completion date: May 2012 --> Apr 2013 Trial primary completion date: May 2014 --> Oct 2014
- NNC 0151-0000-0000 / Novo Nordisk
Trial withdrawal: An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Aug 15, 2014
P1, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
Trial primary completion date: May 2014 --> Oct 2014 Terminated --> Withdrawn
- Enrollment change: Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=32, Completed, Sponsor: University of Virginia
Terminated --> Withdrawn N=12 --> 32
- DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Enrollment change: Effect of NN5401 in Japanese Subjects With Type 1 Diabetes (clinicaltrials.gov) - Aug 15, 2014
P1, N=21, Completed, Sponsor: Novo Nordisk A/S
N=12 --> 32 N=29 --> 21
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: KILOS: Observational Study on Levemir (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=580, Completed, Sponsor: Novo Nordisk A/S
N=29 --> 21 N=365 --> 580
- Enrollment change: An Observational Study to Compare the Safety and Effectiveness of NovoMix (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=3131, Completed, Sponsor: Novo Nordisk A/S
N=365 --> 580 N=2589 --> 3131
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: An Observational Study on Efficacy and Safety in Subjects Using Levemir (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=798, Completed, Sponsor: Novo Nordisk A/S
N=2589 --> 3131 N=1000 --> 798
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment change: Observational Study of Safety and Tolerability of Levemir (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=2286, Completed, Sponsor: Novo Nordisk A/S
N=1000 --> 798 N=3299 --> 2286
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Trial primary completion date: A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs) (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=50, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=3299 --> 2286 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Dec 2014
- | naproxen/esomeprazole / Generic mfg.
Enrollment closed, Trial primary completion date: A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) (clinicaltrials.gov) - Aug 15, 2014
P4, N=45, Active, not recruiting, Sponsor: Horizon Pharma, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Mar 2015
- | AMP-110 / AstraZeneca, Daiichi Sankyo
Trial completion, Enrollment change, Trial primary completion date: Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Aug 15, 2014
P1, N=26, Completed, Sponsor: Amplimmune
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Mar 2015 Active, not recruiting --> Completed | N=21 --> 26 | Trial primary completion date: Dec 2013 --> Jul 2014
- |||| fosdagrocorat (PF-04171327) / Pfizer
Trial completion: Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis (clinicaltrials.gov) - Aug 15, 2014
P2, N=323, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed | N=21 --> 26 | Trial primary completion date: Dec 2013 --> Jul 2014 Recruiting --> Completed
- Amevive (alefacept) / Astellas
Trial completion: T1DAL: Inducing Remission in Type 1 Diabetes With Alefacept (clinicaltrials.gov) - Aug 15, 2014
P2, N=49, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Expiratory Muscle Training for Persons With Neurodegenerative Disease (clinicaltrials.gov) - Aug 15, 2014
P2/3, N=90, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| omeprazole / Generic mfg., cyclosporine / Generic mfg.
Phase classification, Enrollment change, Trial initiation date: The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients (clinicaltrials.gov) - Aug 12, 2014
P2/3, N=130, Not yet recruiting, Sponsor: Perle Bioscience, LLC.
Active, not recruiting --> Completed Phase classification: P3 --> P2/3 | N=60 --> 130 | Initiation date: Feb 2014 --> Feb 2015
- |||||| Enrollment open: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (clinicaltrials.gov) - Aug 11, 2014
P3, N=70, Enrolling by invitation, Sponsor: CSL Behring
Phase classification: P3 --> P2/3 | N=60 --> 130 | Initiation date: Feb 2014 --> Feb 2015 Not yet recruiting --> Enrolling by invitation